Janice M. Mehnert

Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial

Alain P. Algazi, Megan Othus, Adil Daud et al. · Nature Medicine · 2020 · 108 citations · Full text

Tumor Biology, Randomized Phase 2, Medicine +9

Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays

Janice M. Mehnert, Mary M. McCarthy, Lucia B. Jilaveanu et al. · Human Pathology · 2009 · 103 citations

Quantitative Expression, Medicine, Melanoma +9

<i>BRAF</i> Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in <i>BRAF</i>V600E Mutant Melanoma

Atul Kulkarni, Husam Al-hraishawi, Srilatha Simhadri et al. · Clinical Cancer Research · 2017 · 61 citations

SWOG S1320: A randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAF^V600E/k mutant melanoma.

Alain P. Algazi, Megan Othus, Adil Daud et al. · Journal of Clinical Oncology · 2015 · 16 citations

Swog S1320, Cancer Management, Immunology +17

VEGF, VEGFR1, and VEGFR2 expression in melanoma

Janice M. Mehnert, Mary M. McCarthy, Salim Aziz et al. · Journal of Clinical Oncology · 2007 · 12 citations

Tumor Biology, Angiogenesis, Oncology +14